Observational studyMedical sciences (Basel, Switzerland)2025
Impact of Elexacaftor-Tezacaftor-Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis.
Matthias Welsner, Florian Stehling, Wolfgang Gruber, Dirk Westhölter, Sivagurunathan Sutharsan, Christian Taube, Erik Büscher, Felix Nensa, Sebastian Zensen, Lale Umutlu and 7 more
Abstract readObservational Study
In one paragraphObservational study in Medical sciences (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Matthias WelsnerDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, Germany.ORCID 0000-0003-1259-8911 Florian StehlingPediatric Pulmonology and Sleep Medicine, Cystic Fibrosis Center, Children's Hospital, University of Duisburg-Essen, 45147 Essen, Germany.
Wolfgang GruberPediatric Pulmonology and Sleep Medicine, Cystic Fibrosis Center, Children's Hospital, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0003-2186-9269 Dirk WesthölterDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, Germany.
Sivagurunathan SutharsanDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, Germany.
Christian TaubeDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, Germany.
Erik BüscherDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, Germany.ORCID 0009-0000-2300-239X Felix NensaInstitute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.ORCID 0000-0002-5811-7100 Sebastian ZensenInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0003-2997-0740 Lale UmutluInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Michael ForstingInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0002-5584-9824 Johannes HauboldInstitute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.ORCID 0000-0003-4843-5911 Luca SalhöferInstitute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.ORCID 0000-0002-5376-3154 Mathias HoltkampInstitute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.ORCID 0000-0002-0719-2207 Judith KohnkeInstitute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.ORCID 0009-0009-8826-3481 Rene HoschInstitute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.
Marcel OpitzInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0001-7455-8590 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundThis study aimed to investigate longitudinal changes in muscle mass, quality, and composition (sarcopenia and myosteatosis) in adult people with cystic fibrosis (pwCF) using artificial intelligence (AI)-assisted body composition analysis (BCA) with chest computed tomography (CT) at the T12 level and to examine the influence of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI).
methodsA retrospective observational study was conducted on 102 adult pwCF (42 females (41%), mean age 33.9 ± 11.1 years) who underwent routine chest CT scans with a minimum of six months between scans. PwCF were categorized into ETI and no ETI groups. AI-assisted BCA was performed on chest CT images at the T12 level to measure skeletal muscle area (SMA), inter- and intramuscular adipose tissue (IMAT), and low-attenuation muscle area (LAMA). IMAT/SMA ratio and height- and weight-related skeletal muscle indices (SMI) were calculated.
resultsThe ETI group showed a significant increase in SMA over time (
conclusionsAdult pwCF, particularly those undergoing ETI therapy, experience significant changes in body composition, including increased muscle mass and myosteatosis. Trends in the development of sarcopenic obesity have been observed, particularly in female pwCF. These findings emphasize the importance of comprehensive body composition assessments and targeted interventions in pwCF treated with ETI to optimize muscle mass and quality while managing adipose tissue accumulation.
Indexed as
AminophenolsBenzodioxolesCystic FibrosisIndolesPyrazolesPyridinesQuinolinesAdultBody CompositionDrug CombinationsFemaleHumansMaleMiddle AgedMuscle, SkeletalRetrospective StudiesAminophenolsBenzodioxolesDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrazolesPyridinesQuinolinesadultsartificial intelligencebody compositionchest-computed tomographycystic fibrosismyosteatosissarcopenia
Identifiers
PMID41440516
PMCPMC12734936
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390